Zinc oxide nanocomposites in the form of coatings and composite films with antitumor activity were obtained by deposition of ZnO nanofilms on surfaces of ethyl ether Sali- cylidene DL-tyrosine (S1) and ethyl ether Sal...Zinc oxide nanocomposites in the form of coatings and composite films with antitumor activity were obtained by deposition of ZnO nanofilms on surfaces of ethyl ether Sali- cylidene DL-tyrosine (S1) and ethyl ether Sali- cylidene DL-tyrosine Cu (II) chelate (S2) by magnetron sputtering of Zn target. Ethyl ether salicylidene DL-tyrosine, Cu (II) chelate of ethyl ether salicylidene DL-tyrosine reveal some anticancer properties. Their zinc oxide nano- composites were obtained in the form of coat- ings (S1 + ZnO, S2 + ZnO) and composite films presenting a mixture of polyvinyl alcohol (PVA) with S1, S2 (S1 + PVA + ZnO, S2 + PVA + ZnO), for the purpose of increasing anticancer activity. Considerable increase in antitumor activity re- veal ZnO nanocomposites with salicylidene amino acid chelates (as distinct from their ethers) in the form of S2 + ZnO (47%) and S2 + PVA + ZnO (48%) in comparison with S2 (20%). Structural, spectral properties of the salicylidene amino acids and their ZnO nanocomposites were studied.展开更多
文摘Zinc oxide nanocomposites in the form of coatings and composite films with antitumor activity were obtained by deposition of ZnO nanofilms on surfaces of ethyl ether Sali- cylidene DL-tyrosine (S1) and ethyl ether Sali- cylidene DL-tyrosine Cu (II) chelate (S2) by magnetron sputtering of Zn target. Ethyl ether salicylidene DL-tyrosine, Cu (II) chelate of ethyl ether salicylidene DL-tyrosine reveal some anticancer properties. Their zinc oxide nano- composites were obtained in the form of coat- ings (S1 + ZnO, S2 + ZnO) and composite films presenting a mixture of polyvinyl alcohol (PVA) with S1, S2 (S1 + PVA + ZnO, S2 + PVA + ZnO), for the purpose of increasing anticancer activity. Considerable increase in antitumor activity re- veal ZnO nanocomposites with salicylidene amino acid chelates (as distinct from their ethers) in the form of S2 + ZnO (47%) and S2 + PVA + ZnO (48%) in comparison with S2 (20%). Structural, spectral properties of the salicylidene amino acids and their ZnO nanocomposites were studied.
